Oncology & Cancer

New data informs treatment of blood cancer during pregnancy

Today, Blood Advances published a study revealing that patients with relapsed/refractory (r/r) lymphoma during pregnancy experienced a progression-free survival rate of 24% and an overall survival rate of 83%. Receiving a ...

Medications

Epkinly granted accelerated FDA approval for lymphoma treatment

The U.S. Food and Drug Administration has granted accelerated approval for Genmab's Epkinly (epcoritamab-bysp) for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLBCL arising from indolent lymphoma, ...

Oncology & Cancer

What is the best lymphoma treatment after CAR T therapy fails?

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend. Typically given to lymphoma patients for whom other treatments have proven ineffective, CAR T therapy involves removing immune cells ...

Oncology & Cancer

Patients with IBD found to be at higher risk of lymphoma

The risk of developing lymphoma is slightly elevated in inflammatory bowel disease (IBD) and has increased in recent years in patients with Crohn's disease, report researchers from Karolinska Institutet in a study published ...

Oncology & Cancer

Novel lymphoma tumor model paves way for new therapies

In recent years, innovative cancer drugs that target specific molecular drivers of the disease have been embraced as the treatment of choice for many types of cancer. But despite significant advances, there is still a lack ...

Medications

Epstein-Barr virus associated tumors and drug repurposing

A new study published in OMICS: A Journal of Integrative Biology identified differentially expressed host and viral microRNAs (miRNAs) in six Epstein-Barr virus (EBV) associated tumors. The study reports several drug candidates ...

page 5 from 40